Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 21%
Sell 7%
Strong Sell 0%

Bulls say

Icon is a global market leader in contract research services for the pharmaceutical and biotechnology industries with an expanding pipeline, strong performance in recent quarters, and efficient operations leading to improved margins. The company's commitment to gender equality and targeted investments in technology and laboratory services highlight their focus on long-term growth. With a diverse and experienced board and workforce, Icon is well-positioned for accelerated growth in the coming years.

Bears say

Icon is facing several fundamental reasons for the negative outlook on their stock. Firstly, there is a risk to the Company's financial reporting and forward guidance due to potential restatements or changes in backlog. Secondly, delays or cancellations in delivering clinical trials on time could harm the Company's reputation with clinical study managers and impact its standing. Lastly, while the Company does prioritize and integrate sustainability considerations into its strategy, it remains unclear how this affects executive compensation and could be a potential risk to investor confidence.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.